| Literature DB >> 29518990 |
Philipp Schwarzer1, Julia Wunsch-Palasis2, Andreas Bechthold3, Thomas Paululat4.
Abstract
Rishirilide B was isolated from Streptomyces rishiriensis and Streptomyces bottropensis on the basis of its inhibitory activity towards alpha-2-macroglobulin. The biosynthesis of rishirilide B was investigated by feeding experiments with different 13C labelled precursors using the heterologous host Streptomyces albus J1074::cos4 containing a cosmid encoding of the gene cluster responsible for rishirilide B production. NMR spectroscopic analysis of labelled compounds demonstrate that the tricyclic backbone of rishirilide B is a polyketide synthesized from nine acetate units. One of the acetate units is decarboxylated to give a methyl group. The origin of the starter unit was determined to be isobutyrate.Entities:
Keywords: biosynthesis; polyketides; rishirilide; streptomyces
Year: 2018 PMID: 29518990 PMCID: PMC5872131 DOI: 10.3390/antibiotics7010020
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Figure 1Structure of rishirilide B.
Figure 2Labelling positions from feeding experiments using different labelled acetates and l-valine.
13C-NMR signals of rishirilide B together with specific incorporations and coupling constants after feeding with [1-13C]acetate (I), [2-13C]acetate (II), [1,2-13C2]acetate (III) and [13c5,15n]-l-valine (IV).
| Pos. | δC
| I(b)
| II(a)
| III | III(c)
| IV | IV |
|---|---|---|---|---|---|---|---|
| 1 | 197.3 | −0.4 | 3.2 | 41 | C-2 | (d) | |
| 2 | 47.9 | 3.8 | −0.6 | 41 | C-1 | (d) | |
| 3 | 83.0 | 0.8 | 4.4 | 51 | C-16 | (d) | |
| 4 | 76.6 | 4.9 | −0.3 | 39 | C-11 | (d) | |
| 4a | 140.8 | − | 6.3 | 64 | C-10 | (d) | |
| 5 | 152.9 | 4.6 | −0.5 | 64 | C-10a | (d) | |
| 6 | 109.9 | −0.4 | 2.6 | 55 | C-7 | (d) | |
| 7 | 126.0 | 7.9 | −0.4 | 55 | C-6 | (d) | |
| 8 | 119.6 | −0.3 | 1.3 | 55 | C-8a | (d) | |
| 8a | 132.2 | 5.1 | −0.6 | 55 | C-8 | (d) | |
| 9 | 125.3 | 0.4 | 3.8 | 64 | C-9a | (d) | |
| 9a | 130.3 | 4.2 | 0.4 | 64 | C-9 | (d) | |
| 10 | 119.3 | 6.7 | −0.3 | 64 | C-10a | (d) | |
| 10a | 126.3 | −0.8 | 2.0 | 64 | C-10 | (d) | |
| 11 | 35.0 | −0.3 | 2.4 | 39 | C-4 | (d) | |
| 12 | 31.1 | −0.03 | −0.2 | - | - | 35 | C-13(c) |
| 13 | 27.9 | −0.2 | −0.1 | - | - | 35,35 | C-12(c), C-14(c), C-15(c) |
| 14 | 22.4 | (b) | (b) | - | - | 35 | C-13(c) |
| 15 | 22.6 | −0.1 | −0.4 | - | - | 35 | C-13(c) |
| 16 | 173.8 | 5.0 | −0.1 | 51 | C-3 | (d) | |
| 17 | 10.1 | −0.3 | 1.4 | - | - | (d) |
(a) Relative enrichments were normalized to peak intensity of the C-14 signal; (b) Reference signal; (c) Supported from Inadequate NMR spectrum; (d) Weak enrichment, pattern similar to [1,2-13C2]acetate incorporation through biosynthetic transformation of valine.
Figure 3Proposed pathway of rishirilide B biosynthesis. (a) cyclisation and decarboxylation; (b) aromatization, oxidation; (c) Bayer-Villiger oxidation; (d) hydrolytic ring opening; (e) aldole condensation.